贝那普利联合氨氯地平治疗高血压的临床疗效分析

目的:探讨贝那普利联用氨氯地平治疗高血压的临床疗效与安全性。方法:将90例高血压病患者随机分为3组,对照组1(n=30)给予贝那普利片治疗,对照组2(n=30)给予氨氯地平片治疗,观察组(n=30)给予贝那普利片联合氨氯地平片治疗,疗程12周,治疗前和治疗后12周,分析和比较各组患者的收缩压、舒张压、血清总胆固醇、甘油三酯、高密度脂蛋白胆固醇水平。结果:观察组的临床总疗效达93.3%,而对照组1和对照组2分别为63.3%、56.7%,均显著低于观察组(P0.05)。经治疗后,观察组的血压降低程度较对照组1、对照组2更显著(P0.05),而对照组1与对照组2之间比较无明显差别(P0.05);观察组总胆固醇、甘油三酯、高密度脂蛋白胆固醇改善情况均显著优于对照组1、对照组2(P0.05)。观察组不适症状的发生率为6.7%,显著低于对照组1(26.7%)和对照组2(23.3%),差异有统计学意义(P0.05)。结论:贝那普利联合氨氯地平治疗高血压的疗效和安全性均显著优于单用贝那普利或氨氯地平,值得临床普及推广。

Analysis of the Clinical Efficacy of Benazepril plus Amlodipinein the Treatment of Hypertension

Objective:To investigate the efficiency and safety of benazepril plus amlodipine in the clinical treatment of hypertension.Methods:90 patients with hypertension were randomly divided into the control group 1 (n=30) which was treated by benazeprilalone, the control group 2(n=30) which was treated by amlodipine alone as well as the observation group (n=30) which was treated by benazepriland amlodipine for 12 weaks. The systolic blood pressure, diastolic blood pressure, serum total cholesterol, triglyceride, and highdensity lipoprotein cholesterol were detected and compared before treatment and 12 weeks after treatment.Results:After treatment, thetotal effective rate of observation group was 93.3%, which was significantly higher than those the control group 1(63.3%) and the controlgroup 2 (56.7%)(P<0.05). The degree of blood pressure reduction of observation group was more significant compared with the controlgroup 1 and controlgroup 2 (P<0.05), while there was no significant difference between the control group 1 and control group 2(P>0.05).The improvement of TC, TG and HDL-C of observation group were obviously better than those of the control group 1 and control group2 (P<0.05). The incidence rate of adverse reactions was 6.7% in the observation group, which was significantly lower than those of thecontrol group 1(26.7%) and the control group 2(23.3%)(P<0.05).Conclusion:The efficacy and safety of benazepril combined with amlodipinewere evidently better than benazepril or amlodipine alone in the treatment of hypertension, which was worthy of clinical popularization.